Phase I/II, Open Label, Dose Ranging Study of the Safety, Tolerance, Pharmacokinetics and Potential Anti-Inflammatory Activity of HE3286 When Administered Orally for 29 Days to Patients With Rheumatoid Arthritis on a Stable Dose of Methotrexate.

Trial Profile

Phase I/II, Open Label, Dose Ranging Study of the Safety, Tolerance, Pharmacokinetics and Potential Anti-Inflammatory Activity of HE3286 When Administered Orally for 29 Days to Patients With Rheumatoid Arthritis on a Stable Dose of Methotrexate.

Completed
Phase of Trial: Phase I/II

Latest Information Update: 13 Jun 2011

At a glance

  • Drugs HE 3286 (Primary)
  • Indications Rheumatoid arthritis
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors Harbor Therapeutics
  • Most Recent Events

    • 13 Jun 2011 Actual patient number 14 added as reported by ClinicalTrials.gov.
    • 14 May 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 19 Jun 2009 Planned end date changed from 1 Mar 2009 to 1 Jul 2009 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top